Gastroenterologists flag clinical remission and its durability as unmet needs in IBD care: survey

Fierce Pharma, July 24, 2026, Zoey Becker  

Despite the size of the ever-growing inflammatory bowel disease (IBD) drug market and its diversity of modalities from JAK inhibitors to IL-23s, unmet needs and treatment gaps remain. 

That’s according to a new paper from Nimbus Therapeutics and Back Bay Life Science Advisors, which surveyed 36 U.S. gastroenterologists to gauge physician perspectives on the current treatment landscape, what’s to come and what they want to see next.